{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:05:22Z","timestamp":1793210722325,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dermatomyositis and polymyositis are rare, idiopathic inflammatory myopathies. Interstitial lung disease is one of the most common and potentially severe extra-muscular manifestations of dermatomyositis and polymyositis and is strongly linked to poor prognosis and early mortality. We aimed to characterise the demographic and clinical characteristics, incidence, and treatment of interstitial lung disease in patients with dermatomyositis or polymyositis. We conducted a retrospective cohort study using the Japan Medical Data Center healthcare claims database. Patients in the database with dermatomyositis (International Classification of Disease version 10 M33.0, M33.1, M33.9) or polymyositis (M33.2) from 01-Jan-2011 until 31-Dec-2019 were identified and followed-up for interstitial lung disease (J84.x) until death, dis-enrolment, or study end (31 December 2020). Cumulative risk curves compared interstitial lung disease risk in dermatomyositis versus polymyositis. Risk factors were evaluated by Cox proportional hazard models. There were\u00a0886 patients with dermatomyositis and 745 patients with polymyositis included in the cohort analysis. Mean (standard deviation) age at dermatomyositis\/polymyositis diagnosis was 46.0 (16.0)\/49.7 (13.3) years and 300 (34%)\/104 (14%) developed interstitial lung disease during follow-up. The incidence rate of interstitial lung disease per 100 person-years was 18.42 (95% CI 16.42\u201320.59) for dermatomyositis and 5.39 (95% CI 4.43\u20136.50) for polymyositis. In the analysis adjusted for sex, age, and comorbidity score, the risk of interstitial lung disease was significantly higher in patients with dermatomyositis than with polymyositis (hazard ratio 2.72, 95% CI 2.18\u20133.41). The rate diverged markedly between the groups in the first year after diagnosis. Risk factors for interstitial lung disease were older age in dermatomyositis, female sex and rheumatoid arthritis in polymyositis. Glucocorticoids with\/without tacrolimus were the most common newly prescribed drugs after the interstitial lung disease diagnosis. In conclusion, the risk of developing interstitial lung disease was significantly higher in patients with dermatomyositis than with polymyositis, and risk factors were different in the 2 patient groups.<\/jats:p>","DOI":"10.1038\/s41598-023-44092-9","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T09:04:39Z","timestamp":1697015079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan"],"prefix":"10.1038","volume":"13","author":[{"given":"Qingqing","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Chih","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choo Hua","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"44092_CR1","unstructured":"Qudsiya Z, Waseem M. Dermatomyositis. In. StatPearls. Treasure Island (FL); 2020."},{"issue":"9197","key":"44092_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(99)05157-0","volume":"355","author":"JP Callen","year":"2000","unstructured":"Callen, J. P. Dermatomyositis. Lancet 355(9197), 53\u201357 (2000).","journal-title":"Lancet"},{"issue":"3","key":"44092_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/clin.1997.4412","volume":"84","author":"DL Jacobson","year":"1997","unstructured":"Jacobson, D. L., Gange, S. J., Rose, N. R. & Graham, N. M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84(3), 223\u2013243 (1997).","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"1","key":"44092_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jdermsci.2019.08.002","volume":"96","author":"M Ogawa-Momohara","year":"2019","unstructured":"Ogawa-Momohara, M. et al. Clinical characteristics of anti-Ro52\u03b1 and anti-Ro52\u03b2 antibodies in dermatomyositis\/polymyositis. J. Dermatol. Sci. 96(1), 50\u201352 (2019).","journal-title":"J. Dermatol. Sci."},{"key":"44092_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge, Z. et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J. Autoimmun. 101, 48\u201355 (2019).","journal-title":"J. Autoimmun."},{"issue":"8","key":"44092_CR6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","volume":"74","author":"C Dobloug","year":"2015","unstructured":"Dobloug, C. et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann. Rheum. Dis. 74(8), 1551\u20131556 (2015).","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"44092_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10067-009-1110-6","volume":"28","author":"IJ Chen","year":"2009","unstructured":"Chen, I. J. et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin. Rheumatol. 28(6), 639\u2013646 (2009).","journal-title":"Clin. Rheumatol."},{"key":"44092_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40064-015-1013-8","volume":"4","author":"S Ikeda","year":"2015","unstructured":"Ikeda, S. et al. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: A retrospective cohort study. Springerplus 4, 240 (2015).","journal-title":"Springerplus"},{"issue":"8","key":"44092_CR9","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.3346\/jkms.2019.34.e55","volume":"34","author":"SK Cho","year":"2019","unstructured":"Cho, S. K. et al. Incidence and prevalence of idiopathic inflammatory myopathies in Korea: A nationwide population-based study. J. Korean Med. Sci. 34(8), e55 (2019).","journal-title":"J. Korean Med. Sci."},{"issue":"5","key":"44092_CR10","doi-asserted-by":"publisher","first-page":"e0155381","DOI":"10.1371\/journal.pone.0155381","volume":"11","author":"L Zhang","year":"2016","unstructured":"Zhang, L. et al. Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: A systematic review and meta-analysis. PLoS ONE 11(5), e0155381 (2016).","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"44092_CR11","first-page":"9","volume":"9","author":"H Kawasumi","year":"2015","unstructured":"Kawasumi, H., Gono, T., Kawaguchi, Y. & Yamanaka, H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin. Med. Insights. Circ. Respir. Pulm. Med. 9(Suppl 1), 9\u201317 (2015).","journal-title":"Clin. Med. Insights. Circ. Respir. Pulm. Med."},{"issue":"2","key":"44092_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/jcm9020407","volume":"9","author":"C Vacchi","year":"2020","unstructured":"Vacchi, C. et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. A narrative review. J. Clin. Med. 9(2), 407 (2020).","journal-title":"J. Clin. Med."},{"key":"44092_CR13","unstructured":"Ministry of Health Labour and Welfare Japan. Guidelines for the treatment of polymyositis and dermatomyositis (2020)."},{"issue":"1","key":"44092_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","volume":"51","author":"KY Sun","year":"2020","unstructured":"Sun, K. Y., Fan, Y., Wang, Y. X., Zhong, Y. J. & Wang, G. F. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020. Semin. Arthritis Rheum. 51(1), 175\u2013191 (2020).","journal-title":"Semin. Arthritis Rheum."},{"issue":"5","key":"44092_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.semarthrit.2020.07.011","volume":"50","author":"KH Ng","year":"2020","unstructured":"Ng, K. H. et al. Risk of interstitial lung disease in patients with newly diagnosed systemic autoimmune rheumatic disease: A nationwide, population-based cohort study. Semin. Arthritis Rheum. 50(5), 840\u2013845 (2020).","journal-title":"Semin. Arthritis Rheum."},{"issue":"3","key":"44092_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/14397595.2013.844308","volume":"24","author":"A Ohta","year":"2014","unstructured":"Ohta, A., Nagai, M., Nishina, M., Tomimitsu, H. & Kohsaka, H. Prevalence and incidence of polymyositis and dermatomyositis in Japan. Mod. Rheumatol. 24(3), 477\u2013480 (2014).","journal-title":"Mod. Rheumatol."},{"key":"44092_CR17","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan, H. et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care 43, 1130\u20131139 (2005).","journal-title":"Med. Care"},{"key":"44092_CR18","unstructured":"American Thoracic Society. ICD-10-CM Coding for interstitial lung diseases. 11 May 2022."},{"issue":"2","key":"44092_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/oxfordjournals.aje.a115507","volume":"131","author":"K Ulm","year":"1990","unstructured":"Ulm, K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am. J. Epidemiol. 131(2), 373\u2013375 (1990).","journal-title":"Am. J. Epidemiol."},{"issue":"12","key":"44092_CR20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s40264-019-00861-y","volume":"42","author":"R Wakao","year":"2019","unstructured":"Wakao, R. et al. Data-driven identification of adverse event reporting patterns for japan in vigibase, the WHO global database of individual case safety reports. Drug. Saf. 42(12), 1487\u20131498 (2019).","journal-title":"Drug. Saf."},{"issue":"5","key":"44092_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.resinv.2018.06.002","volume":"56","author":"S Saito","year":"2018","unstructured":"Saito, S., Lasky, J. A., Hagiwara, K. & Kondoh, Y. Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective. Respir. Investig. 56(5), 375\u2013383 (2018).","journal-title":"Respir. Investig."},{"issue":"1","key":"44092_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4143\/crt.2014.201","volume":"48","author":"SH Beom","year":"2016","unstructured":"Beom, S. H. et al. Gefitinib-induced interstitial lung disease in Korean lung cancer patients. Cancer Res. Treat. 48(1), 88\u201397 (2016).","journal-title":"Cancer Res. Treat."},{"issue":"1","key":"44092_CR23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/1346-8138.14604","volume":"46","author":"H Kohsaka","year":"2019","unstructured":"Kohsaka, H. et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. J. Dermatol. 46(1), e1\u2013e18 (2019).","journal-title":"J. Dermatol."},{"key":"44092_CR24","unstructured":"e-Stat. Portal Site of Official Statistics of Japan. 2020 Population Census. Statistics of Japan. (2020)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44092-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44092-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44092-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T22:09:47Z","timestamp":1700518187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44092-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44092"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44092-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"26 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are or were, employees of Janssen Research & Development LLC at the time of the study. HQ and YL hold stock in Johnson & Johnson.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17172"}}